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Abstract 
The disruptive action of an acute or critical illness disease is frequently manifest through rapid 
biochemical changes which may require continuous monitoring. Within these changes, 
resides trend information of predictive value, as well as responsiveness to therapy. In contrast 
to physical variables, biochemical parameters monitored on a continuous basis are a largely 
untapped resource because of the lack of clinically appropriate monitoring systems. This is 
despite a huge testing repertoire opening up in recent years in relation to discrete 
biochemical measurement. Electrochemical sensors offer one of the few routes to obtaining 
continuous readout and, moreover, as implantable devices information referable to a specific 
tissue location. This review focuses on new biological insights that have been secured through 
in vivo electrochemical sensors. In addition, the challenges of operating in a reactive, 
biological, sample matrix are highlighted. Specific attention is given to the choreographed 
host rejection response as evidenced in both blood and tissue and how this both limits sensor 
life time and the reliability of its operation. Examples will be based around ion, O2, glucose 
and lactate sensors because the importance of this group in acute health care.   
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Physiological processes operate under highly dynamic conditions conditioned by a multitude  
biofeedback systems operating on both long and short term timescales. These establish a 
homeostatic control within finite set limits. It is the essence of any multi-cell and tissue 
organism that it is able to maintain relative internal stability in the face of unpredictable, and 
often undesired, environmental change. Within the cell itself, sensitive surveillance 
mechanisms recognise status deviation and effect timely responses, on an ultrafast basis if 
deemed necessary. These responses are all the more effective when delivered through 
specialist tissues and the major organs. Complexities at cell level are only partially reflected 
in changes in the extracellular space. However, it is only the changes here that we are able to 
monitor and assess through available sampling and measurement capabilities. For some 
extracellular parameters, these changes take place on compressed time scales and justify 
frequent, if not continuous, measurement for both a better understanding and for the 
management of with disease. These variables can be considered labile and their dysregulation 
represents a major failure of homeostatic control. Currently, these centre on ions, gases and 
small metabolites. Their potential for undergoing rapid change is also indicative of the 
potential value of continuous monitoring to track their trajectory and to help titrate therapy. 
The timing of any therapy is of equal importance to its amount in certain types of critical 
illness, and may influence recovery and survival.  
 
For all practical purposes, only extracellular events are trackable. Moreover, the fractal and 
multi-organelle architecture of the cell does not readily offer simplified messages that allows 
easy conclusions about its status or that of the whole individual organism. This remains the 
case even if robust microsensors were to become available. A clear differentiation between 
normal and disease is vital clinically, and whatever the biological value of intracellular 
monitoring, any information thus secured  comprises a complicated case mix affected by cell 
ageing, the cell cycle, compartment sampled, the reaction of the cell and a myriad of other 
unknowns that are not easily synthesised into workable diagnostic formulations.  The 
occasional exception is where disease disruption is so overwhelming that it leaves a 
substantial intracellular signature bordering on structural change such as or when an 
insoluble end product accumulates or a core metabolic process is involved as in some 
inherited metabolic diseases. 
 
The earliest effort with sensors for was indeed directed at intracellular monitoring, but for 
enhancing biological understanding. This involved pioneering work with wire and 
micropipette electrodes. The latter as ion selective electrodes were particularly prominent, 
and were used to variously follow intracellular H+, K+ and Na+, in part to study cell plasma 
membrane exchanges. A particular interest was excitable tissues such as nerve and muscle 
[1] where ultra-rapid ionic exchanges mediate membrane depolarisation and launch action 
potentials. Such work initiated our understanding of cell and physiology and its ability to 
function at high speed. Oxygen was the other intracellular target, enabled through more 
robust wire-based electrochemical sensors [2]. Priority interest in oxygen emanated from, 
and remains, its central importance to the energy economy of the cell and the dire 
consequences of its deficiency.  
 
The cell, tissue and whole organism hierarchy gives us a dimensional scale across which we 
can select monitoring options at the supra-cellular level. For clinical purposes, it is at the 
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whole organism end of the range that we can see direct clinical value. This larger scale is 
fortunately readily accessible to us via the circulation, accommodating invasive probes. 
Whole body physiology targeted this vascular access to understand change in the intact 
organism.  The current medicine paradigm is the use of blood as the ultimate pre-mixed 
representative of whole-body change. Whilst blood is core to our disease understanding, it is 
still an approximate messenger, affected differentially by different tissues and with a 
compositional change that may also be a diluted version of events at local level. Our access 
and assay technologies in the clinical laboratory are inevitably directed at blood. A typical 
biochemistry repertoire is 200 parameters, a triumph for analytical science [3], but one less 
attentive to tracking rapid change other than by more discrete measurements. Yet we already 
know the value of continuously monitoring oxygen, certain ions and metabolites in blood. 
 
Other fluids such as urine and CSF might have discrete measurement value, but continuous 
monitoring is unlikely to be of additional benefit. The tissue biopsy [4] for targeted analysis 
lies at the extreme end of the scale for any repeat measurement need. The developing blood 
biochemistry repertoire has made it possible to gain a better picture of the timescale for 
variation. Homeostatic control, far from creating a biochemically static environment, effects 
a pattern of pre-set cycles and modulations. Chronobiologists have elucidated such patterns 
for the healthy state, segregated variously into ultradian, circadian and other longer-term and 
less well understood forms of biorhythm [5]. In disease, there is not only a deviation from set 
points for a biochemical parameter, but moment to moment fluctuation which may change 
in character and contain added information. This goes unrecognised because continuous 
tracking is not available, and the nominally trivial. Rapid change possibilities were understood 
in relation to monitored blood gasses: pH, pO2, pCO2 [6,7]. However, from what we now know 
of glucose and lactate, these and other intermediate metabolites may well exhibit rapid 
change. 
 
Fig 1 Arterial blood pH monitored extracorporeally at a carotid artery loop in an anaesthetised cat 
using a glass pH electrode. End tidal CO2 was monitored by an infrared CO2 analyser. Administration 
of 2% CO2 led to increased end tidal CO2 and a drop in arterial pH. The pH trace also shows breath to 
breath arterial pH oscillations. Adapted from [12]. 
 
In examples relating to ions, continuous monitoring of blood was undertaken in animals using 
ion selective electrodes (ISEs) in early physiology studies on animals [8-11]. Striking rates of 
change were seen. These studies were remarkable in being well before the advent of the 
Carotid artery pH during respiratory cycle  
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microfabrication toolkit for reproducible miniaturisation. In one example, rapid change to 
arterial blood pH was shown a result of increased inspired CO2 content (Fig 1) [12]. Conversion 
of CO2 to carbonic acid by carbonic anhydrase in red cells, we know, is rapid, but its 
manifestation as a matched fast outcome seen through blood [H+] change is a useful dynamic 
indicator. More remarkable, perhaps, was the observation, as in this study, of breath to 
breath pH oscillation due simply to breath to breath pulmonary tidal pCO2 variation.  The 
oscillation is a stable, and remarkable for being observable in the highly buffered entity that 
is whole blood. Interestingly, the amplitude of the oscillations also parallels the respiratory 
CO2 excursions. The nature of oscillations in respiratory illness and compromised blood 
buffering remain an unknown, but could provide new clinically relevant information. 
However, only a fast response ISE with its millisecond response has the capability of unmask 
such hidden variables. Sensor advances, combined with signal processing, might provide a 
valuable step forward in extracting and processing such hidden information. Technically, the 
active membrane components used in ISEs have changed little, a tribute to the early chemists. 
However, other new design iterations could be usefully pursued. An ion selective membrane 
for bicarbonate ion has yet to be made, yet bicarbonate ion has a huge importance for the 
acid-base status of the body in disease, and its dynamic variation unknown.  
 
A classical basis for the in vivo sensor is its ability to follow a trend and thereby pick up 
deviation early, whilst a parameter remains within the bounds of normality. With wider 
deployment of such in vivo sensors, there will be greater identification of early variation and 
of hidden dynamic patterns linked to disease. Minor oscillatory and minimal changes will need 
high resolution sensing. Rapid response will also be crucial, as shown with pH. On speed of 
response, however, it is probable that slower biosensor tracking of metabolic fluctuations will 
still be useful. Oscillatory cycles for basal insulin and glucagon have been observed in blood, 
and are relatively slow, on timescales of minutes. They also have a synchrony with glucose 
oscillations of similar periodicity [13], though this glucose cycling has an amplitude of merely 
0.05 mM. Future sensors able to track such minor cycling behaviour could allow linkage to be 
made to metabolite control and its dysregulation;  
 
Dynamics of oxygen change at the tissue level were the focus of some early studies. These 
helped to unravel interrelationships between oxygen delivery centrally and localised tissue 
oxygen distribution. The latter is modulated by local microcirculation, itself in a state of 
dynamic flux. Silver [14,15] investigated normal and solid tumour tissue pO2 using 
microelectrodes; Lubbers [16,17] used multi-wire electrodes and tracked both oxygenation 
variability and microenvironment heterogeneity. Time dependent shunting of O2 was 
regularly seen, with complex cycling, that was topologically connected to the structure of the 
vascular bed. The interstitial tissue space was thus confirmed, for oxygen at least, as a seat of 
complex gradients; here these reflected a balance of cell respiration against the undulations 
in local blood supply. 
 
A physiology study may only require a sensor to operate for a limited period, and this also 
under highly supervised, conditions. Progression to medical use poses a more severe 
challenge where simplified, robust operation is key. Technical refinements and 
miniaturisation have moved the field along in analytical chemistry terms, but stable in vivo 
embedding and communication has proved a more protracted challenge. In the absence of 
reference methods, monitored output is always a combination of true metabolic readout and 
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uncertain, artefactual change due to implant site tissue changes, including those that cause 
fouling on the device sensing surface. The balance may well be towards a meaningful readout 
and not artefact, but the latter can prove remarkable mimic of real change. The 
communication interface with tissue or blood is the weak link. Interface stability is under 
constant threat from an assembled biological reactivity that changes the very environment 
intended as a sampling window into whole body change. Our understanding of the complexity 
of both the process and it structural end products is still limited. Innumerable sensor design 
approaches, including of new transduction routes, have been reported to combat the adverse 
effects in the host environment, but success has been partial. For tissue, especially, the sensor 
is merely another foreign intrusion, and it is of no consequential difference to the biology as 
to whether it has been architectured as an ‘intelligent’ material or some standard unreactive 
biomaterial. Emphasis is needed on the biology now to find a route to reliable monitoring and 
the promise it brings. Recent work has begun to consider these extra-sensor processes and 
their key elements. The balance of work, though, still does not reflect the centrality of the 
biological question. Biomaterials research certainly provide a guide, but sensing research 
needs its own approach now. On this aspect, the review summarises the response basics in 
blood and tissue, and how these can affect sensor performance. Examples of dynamic 
monitoring, however, show why the effort is worthwhile.  
 
2. Sensors for continuous intravascular monitoring 
2.1 Ion selective electrodes 
The ISE has two intrinsic advantages for monitoring. Firstly, it responds on the basis of facile 
ion binding and not slow diffusive access to deeper structures. This delivers a response time 
within milliseconds. Secondly, the response is on the basis of equilibrium ion binding, so a 
maintained ion flux to the device at steady state is not needed. The first allows unmasking of 
rapid transients (Fig 1), the second is far less affected by surface fouling, other than possibly 
by aa slower readout or if the deposited layer itself has charge effects which alter membrane 
potential. ISE biological use has thus been mostly without modification to in vitro device 
membranes. Indeed, a material as unpromising and as bioincompatible as a glass pH 
membrane is usable in biological fluids in the first place because of its independence from 
continued ion flux for stable readings. The more central issue for ISEs in vivo, though, is the 
potential toxicity of incorporated ionophores and plasticisers. Though quantitatively small, 
they are biologically active and toxicologically risky; the standard plasticiser 2-nitrophenyl 
octyl ether, for example is pro-inflammatory and ionophores can have cell membrane effects. 
 
In the main, in vivo studies have focussed on K+. It is of predominantly cellular origin, and its 
abnormal release can both reflect and cause alter the stability of instability in excitable 
neuromuscular tissue.  In an early animal study, Hill et al [18] devised a flexible intravascular 
catheter sensor for K+ with a membrane comprising the K+ ionophore valinomycin in PVC and 
achieved low drift monitoring with catheter mechanical compliance matched to intravascular 
use. A tip diameter of 0.6mm enabled safe small vessel insertion without flow obstruction. 
Femoral vein catheterisation in humans was achieved with a low drift (<3mV/h) catheter 
which enabled monitoring of rapid K+ efflux from muscle during exercise; K+ transients of <0.1 
mmol/L were picked up [19]. The pressure artery pose a further catheterisation risk, but 
arterial catheterisation has also been reported. In an animal study using a carotid artery 
catheter, rapid K+ release from carotid body oxygen chemoreceptors was monitored during 
hypoxia stimulation [20]. The benefits of a precise localisation of a sensor tip was shown using 
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a catheter advanced into the coronary sinus of the heat in human studies. This vessel serves 
as the common venous conduit for blood from the heart. In patients suffering from 
myocardial ischaemia, K+ transients were shown which would have been undetectable within 
the general circulation [21]. K+ release from myocardium, moreover, is correlated with the 
severity of ischemia [22].  
 
Rapid blood Ca2+ transients have also been shown using indwelling vascular catheters. In one 
report, a synthetic Ca2+ ionophore was used to functionalise a plasticised PVC membrane [8]. 
In a study on dogs, cardiac venous drainage showed Ca2+ perturbation due to the injection of 
ionised X-Ray contrast agent [23]. With glass being unacceptable for in vivo use, pH catheters 
have been made using H+ affinity polymer and H+ ionophore, octadecyl isonicotinate [24]. 
When applied to coronary sinus monitoring, blood pH change could be tracked in cardiac 
ischaemia patients [25]. 
 
2.2 ISE biocompatibility 
The active ionophore of an ISE is typically a high affinity, high reversibility binding agent, and 
if diffusible could pose a risk in vivo. The direct consequence is permeabilization of the cell 
plasma membrane. The quantities used for small in vivo ISE membranes are insufficient for 
systemic toxicity, but could still pose a local tissue risk; regulatory approval I any case would 
necessitates extensive testing. Discovery research for new ISE membranes may well extend 
our analytical reach for ions, but now should preferably combine biological with chemical 
screening. Cánovas et al [26] undertook such combined evaluator studies of ISE membrane 
components and tested cytotoxicity in vitro, notably for valinomycin, the most efficient K+ ISE 
ionophore to date. Inevitable toxicity, and the antibiotic mutacin, a polycyclic peptide, was 
suggested as a possible alternative ionophore for K+. Much, of course, depends on how much 
of an ionophore will leach out, and this in turn will be a function of membrane 
permeabilization due to co-entrapped plasticiser. The plasticisers assessed in this study 
showed varying degrees of toxicity, and reinforce the principle of pre-use testing. The 
polymeric component of the ISE membrane should not be a toxicity concern. A polymer is 
only really toxic in so far as it releases small molecule constituents. This could possibly arise 
from biological degradation, as seen with polymeric biomaterials. The reactive implant site 
has high degradation potential with its constituent hydrolytic enzymes, lowered local pH and 
free radicals release from activated phagocytic cells. So again, biological screening needs to 
be part of any new polymer development, other than in the case of established PVC or 
polyurethane.  
 
ISE surface modifications and coatings for safe retention of diffusible components is unlikely, 
given the parallel need for ion permeability. However, the possibility exists for reducing 
surface biofouling by a coating. Pharmacologically active agents for stabilising blood platelets 
at the surface could help mitigate fouling, and surface hydrophilic layers such as of 
polydopamine [27] and hydrogels such as poly(2-hydroxyethyl methacrylate) (pHEMA) [28] 
have been reported. Zwitterionic phosphorylcholine is integral to the outer red cell 
membrane surface, and can confer a degree of haemocompatibility [29]. Other biologically 
inspired molecules have also shown some effectiveness.  Surface immobilised heparin [30] 
was used, and a NO adduct within a membrane released thrombus countering free NO [31].  
Heparin had the facility to bind antithrombin and thereby to concentrate its anticoagulation 
effect at the surface, and the ubiquitous signalling molecule provided surface protection 
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through its platelet passivating action. As with any small molecule agent, including the 
mediators used for second generation enzyme biosensors, whenever a new component is 
contemplated, the risks of agent toxicity need also to be considered alongside the analytical 
benefits. 
 
A further factor for any intravascular component is progressive thrombosis at points other 
than the sensing surface. The results could be flow blockage or disseminated thrombi to 
distant tissue locations. Materials for surface biocompatibility are often tested over only 
limited periods, and in vitro, so whatever promise is shown, may not transfer to in vivo 
deployment. One factor is vascular flow; platelets are highly sensitive environmentally, and 
become activated even by local turbulence, so surface deposits may occur under flow 
disruption regardless of a high materials surface haemocompatibility.   
 
Future designs for ISEs, if used intravascularly, will need an integrative approach whereby not 
just the sensing surface, but also the flow compatibility of the entire construct will need 
optimsation. The starting point, though, is the appreciation of the scale of the in vivo 
biological challenge with blood. Testing with blood sub-components in focussed studies and 
under controlled conditions can only serve for initial screening. There is a limit to the practical 
value of such a reductionist strategy, and an ever-present risk of overoptimistic assumptions 
about a new material or surface delivering almost what was needed. Whole blood is a high 
alert, rapid response system that features multiple cooperative systems. It is able to harness 
a combination of cellular effectors like a tissue and is not dependent on diffusible, humoral 
signalling agents. It has been evolved to recognise, package and potentially degrade any 
foreign surface intrusion, both as part of fail-safe haemostasis and as a means of partitioning 
any 3D object within the circulation. Later parts of the blood response, in fact, begin to 
resemble those of tissue. From a first, transient, foreign surface encounter, it generates a 
coagulation cascade for thrombus formation accelerating through multiple enzymes and 
finally reaching an explosive rate in its mass generation of the final fibrin crosslink. It also has 
a complementary complement cascade that delivers surface coating protein (viz C3b) the 
promotes phagocytosis, amongst other effects, including promotion of inflammatory change. 
ISE in vitro to in vivo transition is challenging and warrants greater symmetry in blood vs 
sensor research if the early gains of sensor design are to be translated to common clinical use. 
It may be attractive to consider an intermediate solution with the use of an extracorporeal 
sensor as part of an external blood circuit. However, this also is not a easy solution; whilst 
greater control over blood flow dynamics, coagulation and calibration are achieved, 
complicated pump flow control and sterility protection are needed, together with a 
cumbersome fluidic supply, so usage would only be appropriate to a high dependency clinical 
care environment. 
 
2.2 Oxygen electrodes 
After the adaptation of O2 polarography to in vitro blood use, using the Clark electrode, the 
measurement principle has changed little. Electrodes use gas selective membranes able to 
reject other solutes and ions to retain an electrolyte film for stable cathodic O2 reduction 
whilst also excluding cell and colloid from the sample to eliminate working electrode fouling. 
The membrane may, for example, be a hydrophobic polypropylene or PTFE. Miniaturisation 
for intra-arterial use has been achieved [32], but is difficult given the need  
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for seamless attachment of inert hydrophobic membrane material to the body of a device. 
Equally, chemical modification for surface haemocompatibility is difficult; functionalisation 
needs harsh treatment. Also, any deposited coating may delaminate, and for any treatment 
a residual exposed hydrophobic surface will promote fouling through the extra tendency of  
a hydrophobic surface to denature adsorbed protein. Denaturation is more likey to trigger a 
host response than a non-denatured adherent protein. Surface fouling for an oxygen sensor 
is important here because response requires a continuous, stable flux of oxygen to the surface 
for a steady state response, in contrast to the ISE.  
 
 
 Fig 2 Double lumen intravascularly placed O2 catheter with haemo-protective NO delivery used in 
rabbit jugular vein. (- ) NO flow protected O2 sensor, (- ) control O2 sensor. Blue filled circles are 
intermittently sampled venous blood pO2 values assayed by in vitro analyser. A) 100% inspired O2 was 
switched to 21%. B) Return to 100% inspired O2 Adapted from [35]. 
 
Vascular catheters as a monitoring route were reported [33,34] in early studies, and a more 
structurally refined catheter model has been one that uses the catheter wall itself, notably 
silicone, as the gas membrane. NO release at such an electrode can offer a degree of 
suppression of surface coagulation. One embodiment used a double lumen silicone cannula 
where NO was electrochemically released from a second lumen nitrite reservoir [35]. Here, 
stabilised O2 output was seen during acute monitoring of hypoxia (Fig 2). Surface coagulation, 
though not entirely eliminated, could still be sufficiently low for extended monitoring subject 
to a maintained NO release. At such a blood contacting device there is also the risk, in 
principle, that blood cells, especially nucleated cells, which are highly active metabolically, 
can act as an oxygen sink, so depressing measured O2 values. Platelets are also active in this 
regard, though not mitochondria deficient RBCs. Ultimately, the blood interfacing problem 
may be amenable to resolution through synergistic use of locally delivered and surface 
retained anticoagulant agent, along with new catheter shape designs to sustain normal blood 
flow profiles. Alternatively, an extracorporeal, multiparameter system is available for 
NO stabilisation of intravascular oxygen catheter sensor  
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neonatal use (VIA LVM Blood Gas and Chemistry Monitoring System, VIA Medical) [36]; blood 
flow here alternates with heparinised calibrant enabling regular, automated, re-calibration.  
 
3 Blood as a reactive sample matrix  
3.1 Protein surface interactions 
Blood-surface recognition utilises multiple, complex pathways which are as yet incompletely 
understood. Both plasma proteins and the formed elements of blood, other than RBCs, have 
a high tendency to adsorb to surfaces. Protein deposition commences within milliseconds, 
and is later amplified through complement and coagulation cascades that deliver a high mass 
surface coatings. This is the start of the thrombus, and though it may be structurally 
indeterminate, it advances through highly organised, controlled pathways. The speed and 
multi-factorial nature of the process makes experimental study difficult. Consideration of the 
idealised situation of a single protein as a monolayer provides a model to understand the 
initial events. Immediately after deposition and attachment of a protein to any surface, 
conformational remodelling is initiated due to non-covalent binding interactions and 
desolvation changes. Essentially, this is protein denaturation, which leads to chain unravelling 
and dimensional expansion. These surface attachments are driven by enthalpy lowering, but 
since attachment also leads to reduced entropy, to compensate, the free loops unravel to 
increase entropic freedom. The molecule has been considered to have a ‘loopy’ conformation 
and hence its surface footprint increases in area. The extent of the unravelling process 
depends on time, and so for a given mass, the area occupied increases (Fig 3) [37]. If in a 
biofouling study, the assessment period is a short one, then in an idealised situation, there 
will be a higher surface mass per unit area than if the time scale is a long one when the protein 
molecules have expanded and fewer are needed for full coverage, ie jamming.  This makes 
for uncertainty in study comparison. In the limit, all molecules unravel and molecular 





Fig 3 Schematic of progressive relaxation of adsorbed protein layer and increase in surface occupancy 
per molecule over time. Amount of protein needed for total confluent coverage (jamming) of surface 
is reduced as time of experimental observation increases. Adapted from [37]. 
Increase in adsorbed protein surface footprint through relaxation  
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The adsorptive behaviour of proteins from blood is orders of magnitude more complicated, 
but still initially driven by thermodynamics. The complexity is summarised by the Vroman 
effect [38]. In any multi-protein system, there is a competitive protein surface binding and 
exchange, not yet fully understood. Early protein adsorbates from certain high concentration 
proteins are displaced by slower arrivals with stronger surface affinity. Typically in this, 
albumin is replaced by fibrinogen. This shifting protein interface creates a changing contact 
surface, and is also the trigger for later biologically mediated cell and fibrin coagulum 
deposits. Some protein denaturation is inevitable at any surface, and this is a stimulus for 
blood activation through the presentation of new protein motifs (epitopes). A different type 
of protein accumulation is activated later via the complement cascade, and is designed to 




Fig 4 Schematic of surface coagulation sequence. A) Initial rapid protein deposition, in milliseconds, 
subject complex, competitive displacement/remodelling via the Vroman effect, eg fibrinogen 
displacement of albumin. B) Surface activated C3 and Factor XII trigger complement and coagulation 
cascades, leading to protein/C3b coating (opsonisation) and fibrin directed at the surface. C) Platelets 
contact with coated protein sets of adhesion response. D Platelet adhesion leads to activation and 
promotion of fibrin clot, later inflammatory cells incorporated.   
 
Efforts to ultimately achieve zero protein adsorption seem unrealistic in respect of 
effectiveness against whole blood biology. An interesting alternative has been suggested by 
Brash [39]. This envisages that if deposition cannot be avoided, then surface directed selective 
protein deposition might be effective. Thus, a surface might be able to selectively invest itself 
with a functional property such as fibrinolysis (plasminogen adsorption) or anticoagulation 
(antithrombin adsorption). Reports on haemocompatible sensor surfaces indicate a 
continued quest for the single ‘magic bullet’ solution where none may exist. General rules, 
nevertheless, may be derived from such studies such as general rules for 
hydrophobic/hydrophilic balance for lower fouling and selected surface chemical properties 
that might link to complement activation [40]. The surface protein profile together with its 
later remodelled form [41] presents the real contact layer for subsequent cellular processes 
organised by blood, and from the start the original engineered or chemically modified surface 
ceases to have direct blood contact, and yet the response of blood to remains as log as it is in 
place.  
Blood surface interaction leading to thrombus formation 
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3.2 Blood biological reactivity 
Following the protein interaction stage, the intrinsic coagulation pathway is initiated by Factor 
XII surface binding. Complement C3, the core driver of the separate complement cascade, 
and causes independent protein coating and opsonisation. Complement C3 is triggered to 
fragment autocatalytically and produces C3b adsorbate for surface opsonisation; a surface 
that is now an attractant for inflammatory cells [42]. There is cooperativity between the 
coagulation and complement pathways, and this later leads to the incorporation of 
inflammatory cells into a developing surface thrombus (Fig 4) [43,44]. 
 
The platelet is the specialist element of blood that really drives the development of a surface 
thrombus and is one of its most prominent constituents. Its study is difficult because of its 
environmental reactivity, including to the very surfaces used to handle it, and its high 
sensitivity to flow induced stress. Its response to the developing coagulum is, moreover, quite 
specific, and involves receptor stimulation. This leads to dramatic change in a platelet, 
including degranulation, shape alteration to a discoid and multiple bridging/aggregation. This 
super-structure of platelets and entrapped fibrin then adds to the growing thrombus [45]. For 
sensors, though the focus has been on surface chemistry, surface physical profile may also be 
important. In one concept, a surface roughness of platelet dimensions (~2um) was considered 
to offer a better match for platelet surface contact and therefore thrombus formation than 
lower dimension roughness giving less platelet purchase [46]. Leukocytes in blood also 
become surface activated [47], are then recruited into the thrombus and promote 





Fig 5 Tissue pO2 changes monitored in single rat during haemorrhagic shock. Sensors at matched 
implantation sites in flank. Initial haemorrhage clamped at reduced BP (40mmHg); saline only 
resuscitation stabilises BP (60-70 mmHg); haemorrhage to exsanguination with extreme, terminal 
drop in BP. Resuscitation regimen would lead to cumulative blood dilution, progressively lowering 
oxygen carrying capacity to peripheral tissue. Adapted from [49]. 
 Dual tissue site/venous blood pO2 divergence during haemorrhagic shock  
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4 Tissue oxygen electrodes 
4.1 Compartmental difference 
The Clark pO2 sensor has also allowed continuous monitoring of subcutaneous tissue pO2 [48]. 
Such a device has enabled tracking of peripheral tissue pO2 during haemorrhagic shock [49], 
but there are indications that there are compartmental differences between blood and tissue. 
This is suggested for this study by an inter-sensor agreement that was greater than with 
venous blood (Fig 5). Measured tissue pO2 was significantly lower than that of blood at the 
later part of the experiment, a possible outcome of subcutaneous circulation shut down. 
Blood pO2 may reflect more general tissue values, eg of the more protected central organs, 
but further studies ae warranted. These changes cannot be unravelled from sensor drift, but 
that was the cause, then the polyurethane membranes used would be exceptionally lacking 
in biocompatibility, moreover, time was allowed for electrode stabilisation post-implantation; 
here, this took two hours. This is the norm, and considered an artefact with all sensors, 
without clear explanation given over mechanisms. These may be complex, but the possibly of 
a tissue functional response, eg microvascular change cannot be ruled out. Mechanical tissue 
damage and microhaemorrhage will certainly occur, but cannot be the full explanation. 
Calibration uncertainty in tissue lends uncertainty to actual tissue pO2 values, which in any 
case will have local differences at the micron scale. Venous rather than arterial blood 
comparison was used for this study, though arterial pO2 is the benchmark for clinical use. 
Arterial changes were only found at a very late stage haemorrhage, with venous blood, 
derived from tissue, more to reflect sensor changes.  
 
The determinants of tissue pO2 under non-haemorrhagic conditions was reported by Gough 
using a silicone membrane covered electrode [50,51]. Again, the same stabilisation delay and 
uncertainties about tissue O2 were observed. They attributed variation in output at an array 
of tissue electrodes to local difference in vascular flow, and observed slow to rapid 
fluctuations of tissue pO2, which they attributed to perfusion variation due to local vasomotor 
vascular control. The challenge with tissue is that of extracting valid physiological information 
in the face of an evolving tissue reaction, essentially a wound site. Surface biofouling raises a 
further uncertainty. A model for oxygen mass transport to the electrode was established [51] 
which indicated that sensor response was limited by local mass transport resistance, whilst 
more remote oxygen delivery was rapid being associated with blood flows. The high 
permeability membrane used here allowed resolution of such extra-sensor effects. Over 13 
weeks these flux sensitive electrodes picked up a tissue reaction that led to decay in tissue O2 
permeability, to ~10% of that in water. Even the local fibrous capsule build-up to 5mm depth 
apparently did not completely abolish diffusive transport. Whist such a high permeability 
membrane can allow investigation of the tissue effects, practical monitoring requires a 
diffusion limiting membrane to negate external transport variables. Even here, over a long 
time period, it may prove difficult to achieve this negation if a substantive fibrous capsule 
forms. With tendon as a model dense collagen barrier, we found micro-solute diffusion to be 
just 1% of that in water [52].  
 
4.2 Tissue micro-heterogeneity 
Tissue oxygen delivery distribution at the microscopic level is a field in its own right, and 
numerous mapping studies of oxygen have been undertaken using microelectrodes [53,54]. 
Micro-heterogeneity is a result of cell uptake, vascular delivery and transport across the 
extracellular compartment. Cerebral tissue has been a particular focus because cortical blood 
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vessels are easily visualised, allowing combined analysis of vascular organisation and pO2 
distribution. In one study, a <5um diameter recess tip electrode with a collodion membrane 
was used to determine blood pO2 along a sequence of arteriole, capillary and venule, along 
with perivascular oxygen distribution [55]. This showed not only the expected pO2 reduction 
along the blod vessel sequence, but steep perivascular oxygen gradients extending ~60um 
into tissue to give pO2 reduction of up to 80% intravascular. (Fig 6). Muscular arterioles of the 
CNS are unique in providing through wall tissue oxygenation, so there are gradients around 
these vessels too. Such work offers insights that may be useful for neurosurgery with a 
detailed picture of oxygen profiles in CNS tissue. Additionally, micro-delivery of vasodilator 
pharmacological agent to a single vessel showed that with relaxation of the arteriolar wall, 






The question arises as to what macro-electrodes can tell us. They offer a ‘field of view’ 
extending hundreds of microns and therefore a sample aggregate of different tissue oxygen 
micro-sites, blurring fractal complexities. The uncertainty is what the exact size of this 
operating might be. The issue is typically bypassed by setting an empirical in vivo calibration 
against blood pO2 from the start. The outcome is still meaningful trend monitoring of pO2, 
as for clinical purposes during compromised tissue oxygen delivery [56-58] and for assessing 
cardiac oxygenation dynamics during ischaemia/reperfusion [59]. A commercial electrode is 
available for specialist CNS use (Licox, Integra Life Sciences Corporation) [60], but there is, as 
yet, no general tissue electrochemical sensor. This commercial system samples through an 
extended 18mm2 area polyethylene tube to capture gross regions of brain. Again, 
CNS tissue axial pO2 profiles around arteriole, capillary and venule 
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uncertainties emanate from the interrelationship between microcirculation organisation, 
flow, vascular distance and mass transport, all balanced against cell metabolic uptake [61].  
Beyond the validation of sensor stability through pre- and-post use calibration, there is no 
simple means of establishing the true pO2 experienced by a device [60]. This is where need 
for disease correlates and diagnostic benefit diverge from the rigour of measurement science.  
Indication of the degree of uncertainty is shown by reported differences in monitoring output 
when the principle of measurements is changed, eg from electrochemical to optical. 
However, trend monitoring is of distinct value, clinically;  in the case of head injury, for 
example, measured hypoxia correlates with outcome. 
 
The CNS is a relatively implant tolerant tissue, a contrast to subcutaneous tissue which 
demonstrates a florid, cellular inflammation. However, at the opposite extreme is when 
inflamed tissue is deliberately probed. The pO2 of inflamed synovial tissue in rheumatoid and 
psoriatic arthritis patients was measured with the Licox probe. Variable degrees of hypoxia 
were seen, and the degree appeared to correlate with disease severity. There was even the 
suggestion that hypoxia was a driver of the inflammation, as manifest by the degree of 
oxidative damage and the degree of hypoxia, and through the vascular damage and 
prevalence of T cells and macrophages [62]. Consistent with this possibility was the 
improvement in oxygenation seen following anti-inflammatory therapy; pO2 doubled from 
~20 mmHg in responders. A pO2 correlation was also demonstrated for T cells, but not for B 
cell infiltration, indicating a disease causal link with the former. An inflammatory milieu 
anything like to this degree at an implant site would radically change measured pO2, no longer 
reflecting systemic levels. Despite the oxygenation correlations seen here with histology, 
there is also the likelihood that high respiring cells simply caused a low tissue oxygen and 
measured levels were simply a functional reflection of the cell population.  
  
 
Fig 7 Percentage frequencies of pO2 measured across A) Normal uterine cervix (7 patients, 432 
samples), (B) Cervical cancer (150 patients, 13596 samples). Shaded areas highlight percentage 
prevalence of extreme tissue hypoxia of <5mmHg. Each set of data represents combined data points 
from multiple patient samples. Adapted from [65].  
 
 
4.3 Cancer tissue 
Solid cancers grow rapidly and can outgrow their vascular supply, already compromised 
through disordered, dysfunctional blood vessels. Zones of hypoxia arise which has clinical 
relevance, because hypoxia confers tumour radio-resistance. A range of analytical techniques 
pO2 distribution microheterogeneity in normal vs cervical cancer tissue 
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have been employed to study cancer blood supply and oxygenation and the field has been 
reviewed [63]. O2 microelectrodes, in particular, have made it possible to unravel the 
oxygenation architecture of cancer tissue. A commercial recess tip oxygen electrode 
(Eppendorf, Hamburg, Germany) housing a 17um gold cathode and a PTFE barrier layer 
enabled sequential tip positioning through tumour tissue at aligned 0.6mm distances [64].  
 
This generated histography data (histography), when combined for tumours from many 
patients in the case of cervical tissue, showed up a stark oxygen distribution difference for 
normal vs cancer tissue. For cervical cancer, for example, median pO2 was a mere 10mmHg, 
compared with normal cervix at 43mmHg, with also a huge preponderance (>60%) of 
exceptionally hypoxic microenvironments (Fig 7) [65]. It is notable that even in normal tissue, 
sites of near zero oxygen levels exist. A hypoxia link to cancer prognosis, however, appeared 
to be absent, but there is value to such study of the oxygen state of cancers. 
 
5 Glucose electrodes  
5.1 Monitoring needs 
Glucose remains the most important target for continuous monitoring. Whilst elegant studies 
exist on the mechanisms and optimisation of enzyme-electrode electron exchange, these 
alone cannot alone translate into operational benefit. Commercial development has helped 
advance this latter operational aspect, initiated with single use strip design [66]. Since the 
early days of glucose sensor development, diabetes has escalated in prevalence, and so 
glucose sensing has risen up the health priority list, along with this, interest in continuous 
monitoring. Diabetes now poses a massive healthcare burden currently affecting 9% of the 
global adult population. In this group are the 5-10% Type I diabetics [67] needing insulin who 
warrant close monitoring to manage histography their therapy. They are also liable to marked 
glucose fluctuations, eg during concurrent illness when in insulin sensitivity changes. The 
brittle diabetes sub-population within this group, though small, has highly unpredictable 
insulin needs and difficult to manage glucose levels; these patients are prone to dangerous 
hypo-/hyperglycaemia [68]. So continuous glucose offers specific benefits to the Type I 
diabetic, with a reduction through improved glucose control of long term vascular and other 
complications.  
 
Sensors when used as single use devices allow for greater design flexibility permitting, for 
example, genetically modified enzyme, leachable/soluble mediator and a modified electrode 
surface. The major consideration here is high shelf life stability and calibration-free 
measurement. Beyond that, survival in blood need only be for seconds. An in vivo sensor, by 
contrast, may be allowed high calibration variation pre-use, but beyond that, stability in use 
has to be sustained over long periods, and the electrode surface, enzyme component and any 
incorporated reagent components need to be guaranteed to be safe, so flexibility over design 
chemistry is limited. Also, intravascular sensors risk disseminated damage, so despite the 
uncertainty tissue is now the target site for continuous glucose monitoring (CGM). 
 
5.2 Clinical realities                                                                                                                          
Measurement based on O2/H2O2 tracking of the glucose oxidase reaction is the basis for most 
CGMs, avoiding additional chemical components and mediators. The exception has been the 
osmium based electron shuttle developed by Heller [69], now used for clinical CGM (FreeStyle 
Libre, Abbott, Almada, US). The sensor is accepted for 14 days use, and ultra low (~2%) drift 
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independent of calibration has been reported [70], considered to be on the basis of a high 
biocompatibility covering membrane. Even during normal dynamic glucose changes there was 
stated here to be concordance with blood glucose values. This system, however, enters a new 
type of unknown into the measurement; devices are manufacturer calibrated to generate 
automatic blood equivalence [71]. This brackets a series of known variables including blood 
vs tissue glucose relation within and between patients, glucose dynamic change modulation 
of this relationship and also any implant site dependence. Studies have shown that all are 
variables affecting response, and should be considered as factors that need to be allowed for 
on an individual basis. Nevertheless, the clinical value of this approach has been recognised 
through improved monitoring benefit to the patient.  
Generally, in the literature the true measured glucose value in tissue is bypassed, as with 
oxygen, and the starting point for data recording is after calibrated against blood in vivo. This 
is really a form of data ratioing across compartments rather than a true calibration, and 
provides no actual information about the tissue state. Modelling of plasma-tissue exchanges 
by contrast recognise delayed and variable exchange kinetics and the need to factor in 
genuine lag times to underpin data correction [72,73].  
 
Added to the physiological uncertainties, there are changes due to the reactivity of tissue at 
the implant site. As yet, no material has been able to claim the stealth performance needed 
to eliminate the disruptive tissue reaction, despite the many sensor design iterations [74-
76].  Performance decay is also maximum in the hours following implantation; the so called 
run-in period of hours to days which warrants separate consideration. 
 
5.2 Membranes and coatings  
The coatings and coverings for glucose sensors have mostly used existing materials. The key 
requirement is low surface fouling and stable glucose and oxygen permeability. Shichiri et al 
[77] were the first to demonstrate such packaging in their use of polyurethane in an 
implanted device. We and others have similarly utilised polyurethane [78,79]. Such 
repurposing of a medical polymer helps reduce the unknown risk of a new material and with 
appropriate porosity and diffusion control enables a response that is sufficiently independent 
of sample physical properties or oxygen background for the clinical glucose range.  However, 
commercial CGM manufacturers have been able to develop and incorporate new materials, 
reviewed by McGarraugh [80]. The Guardian Minimed (Medtronic) employs a block 
copolymer polyurethane with a glucose permeable hydrophilic diol phase for glucose, 
balanced against a silicone that would presumably be O2 only permeable; the DexCom 
(DexCom Inc) uses a hydrophobic/hydrophilic polyurethane mixture for balancing diffusive 
transport with presumably a similar differential permeability intended. Part of the design goal 
for materials here will be the minimisation of oxygen diffusion limitation for the enzyme 
reaction. In the absence of mediator transmembrane transport selectivity provides an 
important means of achieving this. The design challenge is the micromolar levels of  oxygen 
concentration in tissue. The FreeStyle (Abbott) departs from the polyurethane platform and 
uses a functionalised vinyl pyridine-styrene copolymer, but here the mediator based device 
is O2 independent. A claim made for the latter was of the absence of tissue encapsulation 




Membrane innovations have also been reported for CGMs on an experimental basis. Moussey 
has advanced a range of compositions that have included a hydroxypropyl methacrylate 
hydrogel coating on polyurethane giving reduced inflammation and fibrosis [81], humic acid 
films that provoked less tissue reaction [82] and a structurally robust epoxy-polyurethane 
which though leading to a fibrous capsule also stimulated vascularisation [83]. In one study, 
a porous polyvinyl alcohol scaffold was used as a covering matrix on the sensor, and this took 
up collagen from the tissue surround, along with new blood vessels. However, the collagen 
barrier effect countered the supply benefit of increased vascularisation [84]. Nafion, a 
perfluorosulphonic ionomer has been extensively studied, and as a tissue contacting sensor 
surface, it has generated a reduced tissue reaction with only a thin fibrous capsule at three 
months [85]. A comparative study of negatively charged membranes as part of a sol gel layer 
utilised Nafion, dextran sulphate and polystyrene sulphonate [86]. Results were similar, with 
thin collagen capsules seen at 12 weeks foreach material. The lack of a difference is a 
reminder that chemical refinement does not necessarily change outcome. Neutral 
polyethylene glycol (PEG) has well recognised antifouling properties and as a tissue contact 
surface provoked less tissue reactivity with reduced cellularity and tissue adherence [87]. 
 
Phosphoryl choline as a cell membrane zwitterion has again been used to reduce protein and 
cell deposition in blood at an intravascular glucose sensor located in the carotid artery of rats 




Fig 8 Auxiliary oxygen sensor current decay in subcutaneously implanted glucose sensors in pigs. 
Data represent 1 week moving averages of daily mean sampled currents and the spread of data for 
60 electrodes. Adapted from [91]. 
 
Application has been transferred to tissue. Following initial combinatorial screening, a PEG 
crosslinked phosphoryl choline polymer was used over a commercial CGM sensor in mice and 
primate studies [89]. Inflammation mitigation by the phosphoryl choline reduced the need 
for repetitive in vivo calibration. Blood to tissue glucose mismatch was reduced, though there 
was still late fibrous capsule development. Phosphoryl choline translation from blood to 
tissue would be a valuable future direction.  Here and for other studies, the possibility cannot 
be excluded of changed surface mechanics, especially with a gel. Tissue is reactive to surface 
Oxygen sensor decay and stabilisation during extended implantation 
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mechanical cues. Whilst not necessarily due to mechanical change, in one study, soft 
electrospun gelatin coatings on polyurethane fibres over sensors reduced fibrous 
encapsulation, compared with non-coated fibre [90].  
 
As an alternative to the registration of H2O2 product, Gough advanced the use of cathodic O2 
measurement. In one study, a surgically fully implanted sensor was operated for a year [91]. 
A dual sensor arrangement was necessitated here, with the second, non-enzymic, O2 sensor 
compensating for background oxygen variation. Glucose oxidase was used in a crosslinked 
gel, and whilst there was a tissue reaction and a steep response decline with the secondary 
oxygen sensor (Fig 8), the dual O2 approach enabled glucose monitoring from two weeks. The 
wide statistical spread seen in responses for different oxygen sensor implants indicated the 
variability of the local tissue response. Whilst a protracted stabilisation delay is an option, it 
would seem so only if long term implantation is contemplated, and that demands a high level 
of confidence in sensor that would need surgical implantation. A subsequent six month 
human study with these sensors demonstrated stable oxygen compensated glucose tracking 
[92]. Collagen capsule imposed response delay was of the order of 10 min, so workable for 
clinical purposes. 
 
5.3 Bioactive molecule release for biocompatibility 
Drug loaded membranes have been reviewed by Ahyeon et al [93]. Dexamethasone, a high 
potency steroid can suppress inflammation and late fibrosis; VEGF (vascular endothelial 
growth factor) can promote vascularisation to augment glucose delivery. Biological 
complexities may be seen, however. Vallejo-Heligon et al [94] found dexamethasone loaded 
polyurethane to both suppress inflammation and to promote neovascularisation, extending 
the sensor operating period; its combination with VEGF, however, led to depression of VEGF 
induced neovascularisation [95]. Despite a high early effectiveness of such loaded 
membranes, reservoir depletion is a potential drawback, especially with thin, low capacity 
membranes. One study instead delivered VEGF from a cannula using an osmotic pump [96]. 
Neovascularisation was demonstrated which was evident to at least 40 days at a tissue 
distance of 1.3 cm. Composite material designs might also extend function life time time. 
Dexamethasone when loaded onto poly (lactic-co-glycolic acid) (PLGA) microspheres of two 
molecular weights provided early and late release with bioactivity retained for 6 months [97], 
determined by the differential degradation rates of the two polymers.  With microspheres 
embedded in porous polyvinyl alcohol (PVA) surface fouling was offset by porosity recovery 
as the microspheres degraded [98]. 
 
Bioactive NO releasing membranes have also been developed [99] with the aim of 
suppressing pro-inflammatory cytokine release and thereby inflammatory cell recruitment. 
Stabilised sensor operation depends again on a maintained NO reserve. Interestingly, here, 
the sensor run-in period was short. A NO effect might offer a clue to this with perhaps a link 
to signalling. NO is electroactive at anodic voltage, but if its interference is constant then 
monitoring would be possible. In regard to this, the authors postulated that a variable 
generation of NO by inflammatory tissue might be a contribute to response instability. 
 
The widening repertoire of clinical therapeutic agents, including biologics, should provide a 
new generation of anti-inflammatory agents. Masitinib a small molecule agent used to treat 
mast cell tumours is one example. Mast cells are central to the tissue response; they are 
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immediately available, undergo ready degranulation and variously release proinflammatory 
cytokines, serotonin and histamine, and so accelerate inflammation. Masitinib works by 
blocking mast cell receptors, thereby suppressing intracellular kinase signalling and stabilising 
the cell membrane.  When used as a release agent in a sensor [100], however, degree of 
limited protective effect was demonstrated, but not as much as might have been expected 
from drug potency. 
 
5.4 Tissue reactivity to implants 
For bulk dependent implant devices, the tissue reaction is of a lower order concern, but for 
surface response dependent sensors, even a minor reaction can have profound effects. 
Looked at in the opposite sense, tissue is actually the more sophisticated sensor. Thus, it has 
mobile surveillance through its constituent cells, a strong capacity for recognising even the 
smallest of foreign body intrusions as ‘non-self’ and an ability to resolve shape; any 3D object, 
however it is packaged, or disguised is readily recognised. From this recognition starting point, 
a cascade is established, embodied in the Foreign Body Reaction. This is designed to degrade 
the intrusion, and failing that, to package and isolate it behind a fibrous capsular wall. It is too 
fundamental a part of the armoury of an organism, linked to its very survival, to be readily 
countered. While the outcome for the technology is adverse, for the biology it is an 
unmitigated success. The current state of the art is that whilst we have dissected the complex 
response pathways, it is our understanding of them that lags behind [101,102]. 
  
 
Fig 9 Schematic of tissue foreign body response in sequence: 1) Rapid protein deposition masks sensor 
surface; deposited layer increases. 2) Tissue neutrophils sense the surface and send chemotactic 
signals, mast cells promote inflammatory background. 2) Macrophages accumulate with population 
reinforcement by blood monocytes. 3) Failure to degrade surface stimulates more powerful 
multinucleated giant cell formation from macrophages, with enhanced signalling. 5) End stage of more 
quiescent collagen formation and cumulative barrier formation by fibroblasts with parallel 
neovasularisation.   
 
On implantation in tissue, as in blood, rapid protein deposition takes place and the device is 
already packaged by a layer that though conditioned by the original surface, itself goes on to 
condition further responses (Fig 9). Early protein reorganisation, layer accumulation and 
denaturation characterise this growing protein layer. The tissue cellular tissue response is 
subsequently effected by specific receptor binding to these adsorbed proteins. The first 
responders are exploratory polymorphonuclear leucocytes (neutrophils), and with mast cells 
Reactive tissue sequence at implant surface  
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they initiate diffuse chemotactic signalling to attract other phagocytic cells (macrophages). 
These amplify the directed signalling and recruit even more macrophages. Factors released 
include PDGF (platelet derived growth factor), TNF-α (tumor necrosis factor alpha) and IL-6 
(interleukin-6). Within this mix are added monocytes from blood, together with 
proinflammatory mediators, replenishing the macrophage pool. If phagocytosis against the 
device fails, macrophages on the surface fuse to make more effective multinucleated foreign 
body giant cells through a trigger that is unknown [103]. There is also an outpouring of 
degradative agents with no other purpose than to solubilise the intrusion, which includes 
acidic cell contents, oxygen free radicals and hydrolytic enzymes. Ultimately, degradation may 
be a highly desirable biomaterials outcome if the agent is a surgical suture, but if it is a sensor 
membrane it becomes a clear problem. Preferential degradation of the soft segments of a 
polyurethane used for glucose sensors illustrates this [104]. 
 
If the implant stimulus persists over days or weeks, a more cellularly heterogenous 
inflammatory cell architecture is built up with added lymphocytes and plasma cells. Healing 
then ensues if there is no outright toxicity. This progresses behind a cell layer adjacent to the 
device, and variously hosts a dense network of inwardly directed blood vessels, fibroblasts 
and macrophages: granulation tissue. This is also the remodelling phase of the response, and 
a precursor to final collagen capsule deposition by fibroblasts. This sequence of events around 
a non-toxic implant is pre-programmed constant, refractory to management with only its 
quantitative aspects varying across different materials [105] or through suppression 
regimens.  
 
5.5 Tissue reaction implications for glucose sensors. 
During implantation, some microhaemorrhage is inevitable. The locally released RBCs can 
then become a sink for glucose, though not for oxygen. After early RBC removal and the entry 
of more actively metabolising nucleated cells, glucose and oxygen access to the sensor can 
both become reduced. Direct injection of macrophages to a sensor implant site reproduced 
this effect [106], but interestingly not lymphocyte injection despite the metabolic activity of 
these cells. Within days, a rapid population change occurs with an order of magnitude 
expansion of neutrophil number followed by a decay and a parallel increase in lymphocyte 
number. No difference in this tissue response was seen in one study, whether or not the 
sensor was operational and releasing H2O2 into tissue [107]. What is a constant with all 
devices is that final fibrous capsule formation is inevitable and becomes the arbiter of what 
is then seen by the sensor. Studies of beyond a week confirm such capsular development and 
its effect on glucose exchange, in one example leading to a 24min delay following intravenous 
glucose [108]. There is a match here also with the tracked arrival time of injected fluorescent 
glucose analogue. Real physiological exchange between blood and tissue is considered quite 
rapid, requiring <5min for completion, so implanted sensors clearly create an artefactual 
delay. 
 
The collagen capsule, far from being a simple, static accumulation of collagen fibres, is an 
evolving structure with its own vascular network and an internal palisade of cells apposed to 
the sensor. Novak et al [109] took this structural duality into account in their modelling of 
glucose transport. They concluded that lag time was determined by capsular thickness whilst 
sensitivity was a function of capsular porosity and local vascularity. Additional effects 
of macrophages and adipocytes metabolism were small here. By contrast, glucose losses 
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due to local cell metabolism were evident in a cell loaded fibrin gel, further accentuated by 
exposure to pro-inflammatory agent [110], highlighting again the cellular influence of an 
inflammatory matrix.  
 
                    Glucose needle sensor combination with tissue microfluidic delivery 
 
Fig 10 A) Schematic of subcutaneously implanted glucose needle electrode within open ended cannula 
for delivering fluid around the implanted sensor to create a limited hydrated zone. B) Subcutaneous 
glucose monitoring in rat () venous blood glucose, tissue glucose at 60µL/h microflow () and at a 
constrained flow of 10µL/h () showing underestimated glucose and total loss of response with 
clamped flow. Bolus tail vein administration of glucose (G) and insulin (I). Adapted from [79]. 
 
Our own studies on implant sensor stability have led us to use a materials independent 
strategy. Whilst inflammation comprises a hypercellular environment with distinct 
histological characteristics, it is also a zone of high, histologically silent, fluid influx due to 
permeabilised capillaries delivering protein rich fluid that is passaged to the lymphatics, and 
part returned to the microcirculation. A balance of hydrostatic and osmotic transcapillary 
pressures driving the fluid flow as enunciated in the Starling mechanism [111]. The device 
here was designed simply to deliver extra protein-free fluid to the implant site. It utilised an 
electrode-cannula coaxial arrangement for low volume fluid delivery to the sensor tip (Fig 10 
A). Subcutaneous tissue has a negative hydrostatic pressure, and the arrangement enabled 
pumpless tissue driven low flow. The resulting locally reduced protein load reduced sensor 
fouling and stabilised response. Response lag time with respect to blood was eliminated and 
measured tissue levels matched blood without in vivo correction.  
 
So far from local glucose being diluted, glucose access was likely to have been enhanced 
through a well hydrated, open structure, interstitial tissue space (Fig 10 B) [79]. So the 
conclusion of the approach is that a fluidized zone of blood equivalence is obtained. As both 
a practical and model system, fluid management of the interstitium could provide an 
alternate means of manipulating the implant environment.  
 
6 Lactate  
As the end stage metabolite of anaerobic respiration, lactate offers a quantitative measure of 
hypoxic and shock states where the peripheral tissue O2 supply is compromised. As such it 
has formed a core means of tracking the severity of such states and their response to 
treatment. It is inevitably subject to rapid change, but despite this, clinical continuous 
monitoring is not available.  Some experimental work on lactate oxidase sensor based in vivo 
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monitoring in brain has been conducted. Here, oxygen co-substrate limitation at the enzyme 
could potentially lead to underestimated lactate levels, so an oxygen discriminating 
membrane has been one option [112]. Alternatively, stoichiometric regeneration of oxygen 
from H2O2 product has been tried using incorporated CeO2 catalytic particles, and improved 
lactate response during brain monitoring in hypoxic rats [113]. As with glucose, without an 
independent reference measurement in tissue, a true tissue lactate level is difficult confirm. 
Direct validation is possible in the case of an intravascular sensor, and anti-thrombotic NO 
release from such a sensor for added device stabilisation has been reported [114]. 
Intravascular electrodes responded rapidly to both lactate administration and hypoxic 
challenge. With subcutaneous deployment, however, a substantially blunted and delayed 
response was seen. Moreover, in this pig model, upper vs lower body implantation altered 
responses. We have also found a blood-tissue discrepancy in shock and subcutaneous site 
dependent output [115].  
 
The scale of the mismatch well exceeds that seen with glucose and suggests that at least 
under shock conditions, there may be an added barrier to lactate release from the circulation. 
This should not occur at the capillaries, which are not selective for micro-solute, but possibly 
in the interstitial tissue space which as a polyelectrolyte may create an ionomeric barrier to 
the lactate anion. In diffusion through cartilage, we found the diffusion  coefficient for 
ascorbate anion to be a small percentage of that for similar size neutral molecules [52].  The 
complexities of blood tissue compartmentalisation are shown in a study of muscle interstitial 
tissue [116]. Here, microdialysis sampling demonstrated tissue lactate at rest to be double 
that of plasma water at rest, and converged with plasma during exercise elevation, whilst 
glucose at rest was about half that of plasma, but again converged during exercise. The results 
indicated that muscle was able to control its extracellular environment. Subcutaneous 
connective tissue will not have this capability. Our exercise study with tissue microdialysis did 
not make a comparison, but showed a blunted lactate response even delayed to the post-
exercise period during which tissue glucose appeared to fall [117].  It is clear, therefore, that 
study of different interstitial locations and comparisons between techniques for lactate are 
needed to help understand intercompartmental exchanges, for if we do not understand 
these, our understanding of events in simply the blood compartment will be limited. 
 
6 Conclusions 
In vivo sensors purposes are a special sub-set of electrochemical sensors, and constitute a 
distinct practical offering compared to fundamental electrochemistry studies on, say, cell 
signalling and CNS neurotransmitters. Unlike many sensor types, including industrial, they 
operate not merely in a hostile environment, but one that is active, reactive and protean in 
its nature. This rather counters the idea of biology as a benign, tolerant matrix presenting 
mild solution conditions. Recruitment of high surface activity and destructive cells in high 
numbers renders the implant site far from representing the normal physiological state locally 
and provides evidence of a contrived effort sensor disruption. Our quest for data immediacy 
on some variables in the acutely ill patient, however, requires just such sensors.  
 
There also remains a need for repertoire expansion into a broader palette of intermediary 
metabolites, as these interact dynamically, and will give added clinical information. Now we 
better understand compartmental differences there is an even stronger case for developing 




Electrochemical sensors have been the mainstay of such endeavours, and this review has 
highlighted the insights they have given us. This reinforces the need to resolve the generic 
problem of biocompatibility. It has been an inappropriate quest in many ways to search for 
the single material or surface the absolves us of this problem – the result has simply been 
more model systems. The quest needs to be far more rooted in study of the reactive biology. 
If nothing else, we have learned that this reactivity is not surface restricted, has a signalling 
hinterland remote from the surface.  
 
By addressing the right issues, electrochemical sensors will be able to expand service from 
physiology to precision medicine. Also, future development of closed loop feedback control 
and autonomous therapeutic management will become feasible. Much of the capability is in 
place, including sensing chemistry, it is the biological control of the implant site that remains 
to be resolved. A far better, multi-parameter, understanding of the individual’s dynamic bio-
signature might emerge, and this would be entirely in step with the needs of individualised 
therapy, currently limited genomic profiling work.  
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